Microglial-driven changes in synaptic plasticity: A possible role in major depressive disorder

Innes, Stuart; Pariante, Carmine M.; Borsini, Alessandra

doi:10.1016/j.psyneuen.2018.12.233

Cited by 56 publications

(39 citation statements)

References 109 publications

(180 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Microglia-driven changes in synaptic plasticity play a role in major depressive disorder as well [121]. Regional variations of microglial molecules in peripheral inflammatory conditions relevant for depression-like sickness behaviors have also been reported.…”

Section: How May Regional Heterogeneity Be Associated With Psychiatrimentioning

confidence: 99%

Microglial regional heterogeneity and its role in the brain

2019

View full text Add to dashboard Cite

Microglia have been recently shown to manifest a very interesting phenotypical heterogeneity across different regions in the mammalian central nervous system (CNS). However, the underlying mechanism and functional meaning of this phenomenon are currently unclear. Baseline diversities of adult microglia in their cell number, cellular and subcellular structures, molecular signature as well as relevant functions have been discovered. But recent transcriptomic studies using bulk RNAseq and single-cell RNAseq have produced conflicting results on region-specific signatures of microglia. It is highly speculative whether such spatial heterogeneity contributes to varying sensitivities of individual microglia to the same physiological and pathological signals in different CNS regions, and hence underlie their functional relevance for CNS disease development. This review aims to thoroughly summarize up-to-date knowledge on this specific topic and provide some insights on the potential underlying mechanisms, starting from microgliogenesis. Understanding regional heterogeneity of microglia in the context of their diverse neighboring neurons and other glia may provide an important clue for future development of innovative therapies for neuropsychiatric disorders.

show abstract

Section: How May Regional Heterogeneity Be Associated With Psychiatrimentioning

confidence: 99%

Microglial regional heterogeneity and its role in the brain

2019

View full text Add to dashboard Cite

show abstract

“…One hypothesis might be that milk sIgA, although is not absorbed in the intestine of the infant (Roux et al, 1977), can still regulate the composition of the gut microbiome, promoting symbiosis between bacteria (Nakajima et al, 2018), and ultimately reducing the expression of distinct pro-inflammatory cytokines, like TNF-α, both at gut and brain level (Sun et al, 2018). Indeed, a reduced neuroinflammation has been shown to ameliorate both neurogenesis and brain plasticity (Borsini et al, 2018(Borsini et al, , 2017(Borsini et al, , 2015Innes et al, 2019;Zunszain et al, 2012), therefore potentially leading to infant better performances in cognitive tasks.…”

Section: Immune Componentsmentioning

confidence: 99%

Nutritional and immunological factors in breast milk: A role in the intergenerational transmission from maternal psychopathology to child development

Benedetto

Bottanelli

Cattaneo

et al. 2020

Brain, Behavior, and Immunity

Self Cite

View full text Add to dashboard Cite

Perinatal psychopathologies affect more than 25% of women during and after their gestational period. These psychiatric disorders determine important biological variations in their organisms, affecting many different physiological and metabolic pathways. Of relevance, any of these changes occurring in the mother can alter the normal composition of breast milk, particularly the concentration of nutritional and inflammatory components, which play a role in child brain functioning and development. Indeed, there is evidence showing that changes in milk composition can contribute to cognitive impairments and alterations in mental abilities in children. This review aims to shed light on the unique intergenerational role played by breast milk composition, from maternal psychopathologies to child development.

show abstract

“…Indeed, over-expression of distinct pro-inflammatory cytokines, including interleukin 1 beta (IL-1β), IL-6, and tumor necrosis factor alpha (TNF-α), has been associated with several neuropsychiatric disorders, such as depression (3,4), as well as neurodegenerative diseases, like Alzheimer's (AD) and Parkinson's (PD) (5,6). In particular, patients with major depressive disorder (MDD) exhibit both increased immune activation and aberrant regulation of brain plasticity (7), which has been linked with abnormal cellular immunity (8). Similar abnormalities have also been reported in PD and AD, which are characterized by a dysregulated immune response, due to hyper-stimulation of microglia to activate distinct inflammatory signaling pathways (9) related to aggregates of alpha-synuclein and beta-amyloid protein, respectively (10,11).…”

Section: Introductionmentioning

confidence: 99%

The Anti-Inflammatory Role of Omega-3 Polyunsaturated Fatty Acids Metabolites in Pre-Clinical Models of Psychiatric, Neurodegenerative, and Neurological Disorders

et al. 2020

Self Cite

View full text Add to dashboard Cite

Inflammation has been identified as one of the main pathophysiological mechanisms underlying neuropsychiatric and neurodegenerative disorders. Despite the role of inflammation in those conditions, there is still a lack of effective anti-inflammatory therapeutic strategies. Omega-3 polyunsaturated fatty acids (n-3 PUFAs) can reduce depressive symptoms and exert anti-inflammatory action putatively by the production of distinct n-3 PUFA-derived metabolites, such as resolvins D (RvD) and E (RvE) series, maresins (MaR) and protectins (PD), which are collectively named specialized pro-resolving mediators (SPMs) and act as strong anti-inflammatory agents. In this review we summarize evidence showing the effects of treatment with those metabolites in pre-clinical models of psychiatric, neurodegenerative and neurological disorders. A total of 25 pre-clinical studies were identified using the PubMed database. Overall, RvD and RvE treatment improved depressive-like behaviors, whereas protectins and maresins ameliorated neurological function. On a cellular level, RvDs increased serotonin levels in a model of depression, and decreased gliosis in neurodegenerative disorders. Protectins prevented neurite and dendrite retraction and apoptosis in models of neurodegeneration, while maresins reduced cell death across all studies. In terms of mechanisms, all SPMs down-regulated pro-inflammatory cytokines. Resolvins activated mTOR and MAP/ERK signaling in models of depression, while resolvins and maresins activated the NF-κB pathway in models of neurodegeneration and neurological disorders. Our review indicates a potential promising approach for tailored therapy with n-3 PUFAs-derived metabolites in the treatment of psychiatric, neurodegenerative, and neurological conditions.

show abstract

Microglial-driven changes in synaptic plasticity: A possible role in major depressive disorder

Cited by 56 publications

References 109 publications

Microglial regional heterogeneity and its role in the brain

Microglial regional heterogeneity and its role in the brain

Nutritional and immunological factors in breast milk: A role in the intergenerational transmission from maternal psychopathology to child development

The Anti-Inflammatory Role of Omega-3 Polyunsaturated Fatty Acids Metabolites in Pre-Clinical Models of Psychiatric, Neurodegenerative, and Neurological Disorders

Contact Info

Product

Resources

About